Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer
March 19 2024 - 7:00AM
Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit
Pharmaceuticals" or "Conduit" or the “Company”) today announced the
appointment of Dr. Joanne Holland as Chief Scientific Officer.
Dr. Holland brings over 20 years of experience to the CSO role
at Conduit, having amassed expertise across the entire development
spectrum. This includes a deep knowledge base in identifying drugs
that can be applied across multiple disease states, combining
research and commercial skills to advance drugs to market, and
working with premier scientific thought leaders. She has a specific
focus in solid-form technology and its associated intellectual
property, having held leadership positions at publicly traded
companies in this space, as well as consulting roles for several
pharmaceutical companies on all matters relating to solid-form
technology. She has successfully shepherded multiple solid-form
candidates from discovery stage into the clinic, and is the author
of over 50 solid-form intellectual property patents. Dr. Holland
earned a PhD in chemistry from the University of Leeds, UK, which
was sponsored by Pfizer, Inc., before starting her career at
companies including Millennium Pharmaceuticals and Stylacats
Limited.
In addition, Conduit has engaged Dr. Jeff Lindeman to consult on
intellectual property strategies as part of the Company’s research
and development of its solid-form candidates. An international
speaker, Dr. Lindeman has authored book chapters on patent
strategies relating to pharmaceutical solid-state forms. Prior to
opening his consulting firm Two Notch Solutions, LLC, in 2009, Dr.
Lindeman founded and then successfully sold J.A. Lindeman & Co.
PLLC (now Raphael Bellum PLLC) and has over 30 years of
intellectual property law experience, including as an adjunct
patent law professor at American University and as a United States
patent examiner. His role with the Company is as a consultant, not
legal counsel.
“The appointment of Jo as Chief Scientific Officer underscores
Conduit’s commitment to optimizing the value of our current
intellectual property assets, while concurrently fostering the
creation of new intellectual property,” said Dr. David Tapolczay,
Chief Executive Officer. “Jo and Jeff have over 20 years of
experience working together, and their new leadership roles will
significantly enhance our intellectual property state,
strategically positioning Conduit for future out-licensing
opportunities.”
About Conduit Pharmaceuticals
Conduit Pharmaceuticals (Nasdaq: CDT) have developed a unique
business model to bring medicines to patients. Its novel approach
addresses unmet medical need and lengthens the intellectual
property for its existing assets through cutting-edge solid-form
technology and then commercializes these products with life science
companies. Conduit is led by a highly experienced team of
pharmaceutical executives, including CEO, Dr. David Tapolczay,
former Chief Executive Officer of UK-based medical research charity
LifeArc; and the Chair of our Board, Dr. Freda Lewis-Hall,
former Chief Medical Officer of Pfizer, Inc. Our Phase II
ready pipeline, which consists of a HK4 Glucokinase Activator
targeting auto-immune diseases and an MPO Inhibitor which we
believe has the potential to treat Idiopathic Male Infertility, has
undergone 20+ Phase I trials in over 1,000 patients.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of the federal securities laws. All statements
other than statements of historical facts contained in this press
release, including statements regarding Conduit's future results of
operations and financial position, Conduit's business strategy,
prospective product candidates, product approvals, research and
development costs, timing and likelihood of success, plans and
objectives of management for future operations, future results of
current and anticipated studies and business endeavours with third
parties, and future results of current and anticipated product
candidates, are forward-looking statements. These forward-looking
statements generally are identified by the words "believe,"
"project," "expect," "anticipate," "estimate," "intend,"
"strategy," "future," "opportunity," "plan," "may," "should,"
"will," "would," "will be," "will continue," "will likely result,"
and similar expressions. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions,
including, but not limited to; the inability to maintain the
listing of Conduit's securities on Nasdaq; the ability to recognize
the anticipated benefits of the business combination completed in
September 2023, which may be affected by, among other things,
competition; the ability of the combined company to grow and manage
growth economically and hire and retain key employees; the risks
that Conduit's product candidates in development fail clinical
trials or are not approved by the U.S. Food and Drug Administration
or other applicable authorities on a timely basis or at all;
changes in applicable laws or regulations; the possibility that
Conduit may be adversely affected by other economic, business,
and/or competitive factors; and other risks and uncertainties to be
identified in the proxy statement/prospectus (as amended and
supplemented) relating to the business combination completed in
September 2023, including those under "Risk Factors" therein, and
in other filings made by Conduit with the U.S. Securities and
Exchange Commission. Moreover, Conduit operates in a very
competitive and rapidly changing environment. Because
forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified and
some of which are beyond Conduit's control, you should not rely on
these forward-looking statements as predictions of future events.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and except as required by law, Conduit assumes no
obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Conduit gives no assurance that it
will achieve its expectations.
Media:Sean LeousICR
WestwickeSean.Leous@westwicke.com +1.646.866.4012
Investors:Bill BegienConduit Pharmaceuticals
Inc.bb@conduitpharma.com
Conduit Pharmaceuticals (NASDAQ:CDT)
Historical Stock Chart
From Oct 2024 to Nov 2024
Conduit Pharmaceuticals (NASDAQ:CDT)
Historical Stock Chart
From Nov 2023 to Nov 2024